Increased risk of hyperglycemia associated with the use of everolimus in patients with cancer: a systematic review and meta-analysis

doi:10.5246/jcps.2015.05.042

Abstract

Abstract:

Everolimus is an orally administered rapamycin analogue that has been approved to treat several types of solid tumors. However, some patients develop hyperglycemia after being treated with everolimus. In this meta-analysis, we aimed to evaluate the incidence and risk of hyperglycemia in patients with cancer who received everolimus. We searched the medical literature, as index in the Cochrane Library, PubMed, EMBASE, and abstracts from the top scientific meetings (AACR, ASCO, and ESMO). Our meta-analysis included the randomly controlled trials published before November 2014. We calculated overall incidence, relative risk (RR) and 95% confidence intervals (CI) using fixed-effects or random-effects models, depending on the heterogeneity among the trials. A total of 3377 patients (everolimus: 1971; control: 1406) from 8 randomized clinical trials were included in the meta-analysis. In the everolimus groups, the incidence of all grades of hyperglycemia was 20.0% (95% CI: 11.0%–29.0%), while the incidence of high-grade hyperglycemia was 6.0% (95% CI: 3.0%–8.0%). Patients treated with everolimus had an increased risk of hyperglycemia as compared with that of controls (all-grade RR: 2.94, 95% CI: 2.34–3.70; high-grade RR: 4.66, 95% CI: 2.75–7.89). Everolimus significantly increased the risk of hyperglycemia. This risk may depend on the tumor type and the everolimus dosage.

Key words: Everolimus, Hyperglycemia, Tumor type, Dosage, Meta-analysis

CLC Number:

R954

Supporting:

Zihan Guo, Yuanyuan Jiao, Zhanmiao Yi, Ran Li, Yanhua Zhang. Increased risk of hyperglycemia associated with the use of everolimus in patients with cancer: a systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(5): 326-335.

References

[1] Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Nat. Rev. Drug Discov. 2009, 8, 627-644 .

[2] Wullschleger, S.; Loewith, R.; Hall, M.N. Cell. 2006, 124, 471-684.

[3] Guertin, D.A.; Sabatini, D.M. Cancer Cell. , 12, 9-22.2007

[4] Aapro, M.; Andre, F.; Blackwel, l.K. Ann. Oncol. 2014, 25, 763-673.

[5] Ravaud, A.; Urva, S.R.; Grosch, K. Eur. J. Cancer. 2014, 50, 486-495.

[6] Iacovelli, R.; Palazzo, A.; Mezi, S. Acta Oncol. 2012, 51, 873-879.

[7] Funakoshi, T.; Latif, A.; Galsky, M.D. Crit. Rev. Oncol. Hematol. 2013, 88, 30-41.

[8] Paplomata, E.; Zelnak, A.; O'Regan, R. Breast Cancer Res. Treat. 2013, 140, 453-462.

[9] Motzer, R.J., Escudier, B.; Oudard, S. Cancer. 2010, 116, 4256-4265.

[10] Ellard, S.L.; Clemons, M.; Gelmon, K.A. . 2009, 27, 4536-4541.Clin. Oncol.J

[11] Mitri, J.; Castillo, J.; Pittas, A.G. Diabetes Care. 2008, 31, 2391-2397.

[12] Fang, H.; Yao, B.; Yan, Y. Diabetes Technol. Ther. 2013, 15, 914-922.

[13] El-Serag, H.B.; Hampel, H.; Javadi, F. Clin. Gastroenterol. Hepatol. 2006, 4, 369-480.

[14] Liao, S.; Li, J.; Wei, W. Asian Pac. J. Cancer Prev. 2011, 12, 1061-1065.

[15] Huxley, R.; Ansary-Moghaddam, A.; Berrington, D.G.A. Br. J. Cancer. 2005, 92, 2076-2083.

[16] Chari, S.T.; Leibson, C.L.; Rabe K.G. Gastroenterology. 2005, 129, 504-511.

[17] Mills, K.T.; Bellows, C.F.; Hoffman, A.E. Dis. Colon. Rectum. 2013, 56, 1304-1319.

[18] Larsson, S.C.; Giovannucci, E.; Wolk, A. Diabetes Care. 2005, 28, 1805-1807.

[19] Michels, K.B.; Solomon, C.G.; Hu, F.B. Diabetes Care. 2003, 26, 1752-1758.

[20] Noto, H.; Goto, A.; Tsujimoto, T.; Noda, M. PLoS One. 2012, 7, e33411.

[21] Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M. BMJ. 2005, 330, 1304-1305.

[22] Zoncu, R.; Efeyan, A.; Sabatini, D.M. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.

[23] Yamanaka, K.; Petrulionis, M.; Lin, S. Cancer Med. 2013, 2, 862-871.

[24] Sivendran, S.; Agarwal, N.; Gartrell, B. Cancer Treat Rev. 2014, 40, 190-196.

[25] Maass, N.; Harbeck, N.; Mundhenke, C. J. Cancer Res. Clin. Oncol. 2013, 139, 2047-2056.

[26] Andre, F.; O'Regan, R.; Ozguroglu, M. Lancet Oncol. 2014, 15, 580-591.

[27] Zhu, A.X.; Kudo, M.; Assenat, E. JAMA. 2014, 312, 57.

[28] Higgins, J.P.T.G.S. Cochrane. This article can be found online at http://handbook.cochrane.org

[29] DerSimonian, R.; Laird, N. Control Clin. Trials. 1986, 7, 177-188.

[30] Higgins, J.P.T.; Thompson, S.G. Stat. Med. 2002, 21, 1539-1558.

[31] Begg, C.B.; Mazumdar, M. Biometrics. 1994, 50, 1088-1101.

[32] Egger, M.; Davey, S.G.; Schneider, M. BMJ. 1997, 315, 629-634.

[33] NCI. This article can be found online at http://ctep. cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

[34] Pavel, M.E.; Hainsworth, J.D.; Baudin, E. Lancet. 2011, 378, 2005-2012.

[35] Yao, J.C.; de Vries, E.G.E.; Tomassetti, P. N Engl. J. Med. 2011, 364, 514-523.

[36] Baselga, J.; Campone, M.; Piccart, M. N Engl. J. Med. 2012, 366, 520-529.

[37] Baselga, J.; Semiglazov, V.; van Dam, P. J. Clin. Oncol. 2009, 27, 2630-2637.

[38] Shiah, H.S.; Chen, C.Y.; Dai, C.Y. Aliment. Pharmacol. Ther. 2013, 37, 62-73.

[39] FDA. This article can be found online at http://www. pharma.us.novartis.com/product/pi/pdf/afinitor.pdf

[40] Amato, R.; Stepankiw, M. Expert Opin. Pharmacother. 2013, 14, 1229-1240.

[41] Zoncu, R.; Efeyan, A.; Sabatini, D.M. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.

[42] Laplante, M.; Sabatini, D.M. Cell. 2012, 149, 274-293.

[43] Fraenkel, M.; Ketzinel-Gilad, M.; Ariav, Y. Diabetes. 2008, 57, 945-957.

[44] Franz, D.N.; Belousova, E.; Sparagana, S. Lancet. 2013, 381, 125-132.

[45] Bissler, J.J.; Kingswood, J.C.; Radzikowska, E. Lancet. 2013, 381, 817-824.

[46] Ohtsu, A.; Ajani, J.A.; Bai, Y.X. J. Clin. Oncol. 2013, 31, 3935-3943.

[47] Bachelot, T.; Bourgier, C.; Cropet, C. J. Clin. Oncol. 2012, 30, 2718-2724.

[48] von Minckwitz, G.; Eidtmann, H.; Loibl, S. Ann. Oncol. 2011, 22, 301-306.